Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Funda Meric-BernstamNizar M TannirOthon IliopoulosRichard J LeeMelinda L TelliAlice C FanAngela M DeMicheleNaomi B HaasManish R PatelJames J HardingMartin H VossTaofeek Kunle OwonikokoBradley CarthonRamaprasad SrinivasanJohanna C BendellYonchu JenkinsSam H WhitingKeith OrfordMark K BennettTodd M BauerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
TelaE and TelaC showed encouraging clinical activity and tolerability in heavily pretreated mRCC patients.